Tnfrsf1b Knockout cell line(CT26.WT)
Catalog Number: KO01222
Price: Online Inquiry
Catalog Number: KO01222
Price: Online Inquiry
Product Information | |
---|---|
Product Name | Tnfrsf1b Knockout cell line(CT26.WT) |
specification | 1*10^6 |
Storage and transportation | Dry ice preservation/T25 live cell transportation. |
Cell morphology | Fibroblast-like, adherent growth |
Passage ratio | 1:3~1:4 |
species | Mouse |
Gene | Tnfrsf1b |
Gene ID | 21938 |
Build method | Electric rotation method / virus method |
Mycoplasma testing | Negative |
Cultivation system | 90%RPMI-1640+10% FBS |
Parental Cell Line | CT26.WT |
Quality Control | Genotype: Tnfrsf1b Knockout cell line(CT26.WT) >95% viability before freezing. All cells were tested and found to be free of bacterial, viruses,mycoplasma and other toxins. |
Gene Information | |
---|---|
Gene Official Full Name | tumor necrosis factor receptor superfamily, member 1bprovided by MGI |
Also known as | p75; TNFBR; Tnfr2; CD120b; TNF-R2; TNFR80; TNFRII; Tnfr-1; TNF-R75; TNF-R-II; TNF-alphaR2; TNFalpha-R2 |
Gene Description | Enables tumor necrosis factor receptor activity. Involved in several processes, including negative regulation of extracellular matrix constituent secretion; regulation of nervous system development; and semi-lunar valve development. Acts upstream of or within several processes, including RNA destabilization; apoptotic signaling pathway; and negative regulation of inflammatory response. Located in membrane raft. Is expressed in several structures, including extraembryonic component; genitourinary system; hemolymphoid system; liver; and trunk. Human ortholog(s) of this gene implicated in several diseases, including Parkinsonism; acne; bone disease (multiple); glomerulonephritis (multiple); and lung disease (multiple). Orthologous to human TNFRSF1B (TNF receptor superfamily member 1B). [provided by Alliance of Genome Resources, Apr 2025] |
Expression | Broad expression in spleen adult (RPKM 20.1), mammary gland adult (RPKM 14.7) and 20 other tissues See more |
We develop gene knockout solutions tailored to customer requirements and the condition of the target gene.
Cas9 Protein
Cas9 mRNA sgRNA
Cas9 Plasmid
Cas9 Virus
A – Exon KO
gRNAs are designed in the introns flanking the exon, targeting non-multiple-of-3 base deletions in the exon, resulting in frameshift mutations.
B - Frameshift KO
gRNAs are designed within the exon, creating non-multiple-of-3 base deletions to induce frameshift mutations.
C - Complete KO
The entire gene coding sequence is deleted, achieving large-scale knockout effects.
KO Strategy Design
CRISPR Plasmid/Lentiviral Vector Construction
Lentiviral Packaging
Cell Transfection/Lentiviral Infection
Drug Selection
Cell Cryopreservation
Quality Control
Sequencing Validation
Monoclonal Cell Line Generation
Pool Efficiency Validation
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.